Literature DB >> 18987434

Molecular determinants of hERG channel block by terfenadine and cisapride.

Kaichiro Kamiya1, Ryoko Niwa, Mikio Morishima, Haruo Honjo, Michael C Sanguinetti.   

Abstract

Block of cardiac hERG K+ channels by the antihistamine terfenadine and the prokinetic agent cisapride is associated with prolonged ventricular repolarization and an increased risk of ventricular arrhythmia. Here, we used a site-directed mutagenesis approach to determine the molecular determinants of hERG block by terfenadine and cisapride. Wild-type and mutant hERG channels were heterologously expressed in Xenopus laevis oocytes and characterized by measuring whole cell currents with two-microelectrode voltage clamp techniques. Mutation of T623, S624, Y652, or F656 to Ala reduced channel sensitivity to block by terfenadine. The same mutations reduced sensitivity to cisapride. These data confirm our previous findings that polar residues (T623, S624) located near the base of the pore helix and aromatic residues (Y652, F656) located in the S6 domain are key molecular determinants of the hERG drug binding site. Unlike methanesulfonanilides (dofetilide, MK-499, E-4031, ibutilide) or clofilium, mutation of V625, G648, or V659 did not alter the sensitivity of hERG channels to terfenadine or cisapride. As previously proposed by molecular modeling studies (Farid R, et al. Bioorg Med Chem. 2006;14:3160-3173), our findings suggest that different drugs can adopt distinct modes of binding to the central cavity of hERG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987434      PMCID: PMC2845965          DOI: 10.1254/jphs.08102fp

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  33 in total

1.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites.

Authors:  J P Lees-Miller; Y Duan; G Q Teng; H J Duff
Journal:  Mol Pharmacol       Date:  2000-02       Impact factor: 4.436

2.  State dependent dissociation of HERG channel inhibitors.

Authors:  D Stork; E N Timin; S Berjukow; C Huber; A Hohaus; M Auer; S Hering
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

3.  Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.

Authors:  E Ficker; W Jarolimek; A M Brown
Journal:  Mol Pharmacol       Date:  2001-12       Impact factor: 4.436

4.  [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.

Authors:  K Finlayson; L Turnbull; C T January; J Sharkey; J S Kelly
Journal:  Eur J Pharmacol       Date:  2001-10-26       Impact factor: 4.432

5.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

6.  Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block.

Authors:  Jose A Sánchez-Chapula; Ricardo A Navarro-Polanco; Chris Culberson; Jun Chen; Michael C Sanguinetti
Journal:  J Biol Chem       Date:  2002-04-17       Impact factor: 5.157

7.  Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.

Authors:  James T Milnes; Olivia Crociani; Annarosa Arcangeli; Jules C Hancox; Harry J Witchel
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

8.  Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.

Authors:  A A Paul; H J Witchel; J C Hancox
Journal:  Biochem Biophys Res Commun       Date:  2001-02-09       Impact factor: 3.575

9.  Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.

Authors:  Sridharan Rajamani; Corey L Anderson; Blake D Anson; Craig T January
Journal:  Circulation       Date:  2002-06-18       Impact factor: 29.690

10.  Physicochemical features of the HERG channel drug binding site.

Authors:  David Fernandez; Azad Ghanta; Gregory W Kauffman; Michael C Sanguinetti
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

View more
  35 in total

Review 1.  Revealing the structural basis of action of hERG potassium channel activators and blockers.

Authors:  Matthew Perry; Michael Sanguinetti; John Mitcheson
Journal:  J Physiol       Date:  2010-07-19       Impact factor: 5.182

2.  High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943.

Authors:  Hongwei Cheng; Yihong Zhang; Chunyun Du; Christopher E Dempsey; Jules C Hancox
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Naja atra venom peptide reduces pain by selectively blocking the voltage-gated sodium channel Nav1.8.

Authors:  Fan Zhang; Changxin Zhang; Xunxun Xu; Yunxiao Zhang; Xue Gong; Zuqin Yang; Heng Zhang; Dongfang Tang; Songping Liang; Zhonghua Liu
Journal:  J Biol Chem       Date:  2019-02-25       Impact factor: 5.157

4.  Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels.

Authors:  W J Crumb
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

5.  Non-sedating antihistamines block G-protein-gated inwardly rectifying K+ channels.

Authors:  I-Shan Chen; Chang Liu; Michihiro Tateyama; Izhar Karbat; Motonari Uesugi; Eitan Reuveny; Yoshihiro Kubo
Journal:  Br J Pharmacol       Date:  2019-07-10       Impact factor: 8.739

Review 6.  KCNH2 pharmacogenomics summary.

Authors:  Connie Oshiro; Caroline F Thorn; Dan M Roden; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-12       Impact factor: 2.089

7.  Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.

Authors:  Kristeen Pareja; Elaine Chu; Katrina Dodyk; Kristofer Richter; Alan Miller
Journal:  Channels (Austin)       Date:  2012-12-06       Impact factor: 2.581

8.  Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.

Authors:  Yan Long; Zuoxian Lin; Menghang Xia; Wei Zheng; Zhiyuan Li
Journal:  Toxicol Appl Pharmacol       Date:  2013-01-08       Impact factor: 4.219

Review 9.  Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice.

Authors:  Attila S Farkas; Stanley Nattel
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

10.  Marine algal toxin azaspiracid is an open-state blocker of hERG potassium channels.

Authors:  Michael J Twiner; Gregory J Doucette; Andrew Rasky; Xi-Ping Huang; Bryan L Roth; Michael C Sanguinetti
Journal:  Chem Res Toxicol       Date:  2012-08-10       Impact factor: 3.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.